Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension
Go back to Pasatru™ (garetosmab-grts) Demonstrates Zero New Heterotopic Ossification (HO) Lesions in Adult Fibrodysplasia Ossificans Progressiva (FOP) Patients During OPTIMA Trial Extension| Regeneron (NASDAQ: REGN) | Delayed: 806.51 -0.97 (0.12%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $807.48 | 52 Week High | $592.36 | |||
| Open | $806.74 | 52 Week Low | $325.35 | |||
| Day High | $813.86 | P/E | 211.68 | |||
| Day Low | $800.24 | EPS | $3.81 | |||
| Volume | 338,564 | |||||



